
On Friday, Novo Nordisk A/S' (NYSE:NVO) board director Mikael Dolsten said he will not seek election to the Board of Directors at the upcoming extraordinary general meeting on 14 November 2025.
Dolsten, who most recently served as the Head of R&D at Pfizer (NYSE:PFE), informed Novo Nordisk that he has decided to withdraw his candidacy to the Novo Nordisk Board of Directors, both as a member and as observer, due to recent personal circumstances unrelated to Novo Nordisk and the Novo Nordisk Foundation.